People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Biotechnology, Pharmaceuticals, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Spruce Biosciences, Inc. | — | Biotechnology | Series C | $191.6M | $274.3M | 2020 |
| Reneo Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $159.4M | $519.3M | 2017 |
| Mirum Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $138.5M | $347.9M | 2018 |
| Amplyx Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $116.6M | $3.2B | 2015 |
| Auspex Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $82.8M | $951.9M | 2009 |
| Plexium, Inc. | — | Biotechnology | Series C | $60.1M | $361.1M | 2025 |
| Lumena Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $51.4M | $1.6B | 2011 |
| Sorriso Pharmaceuticals, Inc. | — | Biotechnology | Series B | $21.3M | $448.9M | 2021 |
| Balance Therapeutics, Inc. | — | Biotechnology | Series B | $21.2M | $7.3M | 2015 |
| Selventa, Inc. | — | Other Health Care | Series A | $5.5M | $100.2M | 2011 |
Michael Grey at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Michael Grey on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ed Mathers | 3 | 11 |
| Edward Mathers | 2 | 12 |
| Tiba Aynechi | 2 | 9 |
| Niall O'Donnell | 2 | 7 |
| Bali Muralidhar | 2 | 3 |
| Edward T. Mathers | 2 | 3 |
| Susan Dube | 2 | 3 |
| Michael G. Grey | 2 | 2 |
| LEON CHEN | 1 | 15 |
| Michael Martin | 1 | 11 |
| Patrick Heron | 1 | 11 |
| Jonathan Leff | 1 | 11 |
| Noubar Afeyan | 1 | 9 |
| David Collier | 1 | 8 |
| Patrick J. Heron | 1 | 7 |
| ANAND MEHRA | 1 | 7 |
| Mitchell Bloom | 1 | 6 |
| Rob Hopfner | 1 | 6 |
| Alan Fuhrman | 1 | 5 |
| Mitchell Mutz | 1 | 5 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.